CD8A and rhabdomyosarcoma: Taken together, we substantiated that APN deficiency directly maintains the activation of CD8+ T cells to inhibit rhabdomyosarcoma growth by suppressing STAT3 activation, indicating a promising APN-based therapy for the treatment of rhabdomyosarcoma.